<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25484927</article-id><article-id pub-id-type="pmc">4255417</article-id><article-id pub-id-type="publisher-id">alzrt276</article-id><article-id pub-id-type="doi">10.1186/alzrt276</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Imaging as a biomarker in drug discovery for Alzheimer&#x02019;s disease: is MRI a suitable technology?</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Merlo Pich</surname><given-names>Emilio</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>emilio.merlo_pich@roche.com</email></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="A2"><name><surname>Jeromin</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>andreasjeromin@gmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Frisoni</surname><given-names>Giovanni B</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>giovanni.frisoni@gmail.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Hill</surname><given-names>Derek</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>derek.hill@ixico.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Lockhart</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>Andrew.2.Lockhart@gsk.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Schmidt</surname><given-names>Mark E</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>MSCHMID4@its.jnj.com</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Turner</surname><given-names>Martin R</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>martin.turner@ndcn.ox.ac.uk</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Mondello</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>stm_mondello@hotmail.com</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Potter</surname><given-names>William Z</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>wzpottermd@gmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Clinical Imaging, Neuroscience DTA pRED, F. Hoffman-La Roche, Grenzacherstrasse 124 CH-4070, Basel, CH, Switzerland</aff><aff id="I2"><label>2</label>Atlantic Biomarkers, LLC, 316 NW 28th Terrace, Gainesville, FL 32607, USA</aff><aff id="I3"><label>3</label>IRCCS San Giovanni di Dio Fatebenefratelli, Laboratory of Epidemiology, Neuroimaging, and Telemedicine, via Pilastroni 4, Brescia 25125, Italy</aff><aff id="I4"><label>4</label>Medical Imaging Science, UCL, London, UK</aff><aff id="I5"><label>5</label>IXICO Ltd, Floor 4, Griffin Court, 15 Long Lane, London EC1A 9PN, UK</aff><aff id="I6"><label>6</label>GlaxoSmithKline, Neurodegeneration DPU R&#x00026;D China, Neurosciences TA Unit, Clinical Unit Cambridge, Addenbrookes Hospital, Cambridge CB2 2GG, UK</aff><aff id="I7"><label>7</label>Experimental Medicine, Neuroscience Therapeutic Area, Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340, Beerse 2340, Belgium</aff><aff id="I8"><label>8</label>Oxford University Nuffield, Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford OX3 9DU, UK</aff><aff id="I9"><label>9</label>Department of Neurosciences, University of Messina, Via Consolare Valeria, 98125 Messina, Italy</aff><aff id="I10"><label>10</label>National Institute of Mental Health, 6001 Executive Boulevard, BG NSC RM 7209, Rockville, MD 20892, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>30</day><month>7</month><year>2014</year></pub-date><!-- PMC Release delay is 12 months and 0 days and was based on the epub date.--><pub-date pub-type="pmc-release"><day>30</day><month>7</month><year>2015</year></pub-date><volume>6</volume><issue>4</issue><fpage>51</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Merlo Pich et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Merlo Pich et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://alzres.com/content/6/4/51"/><abstract><p>This review provides perspectives on the utility of magnetic resonance imaging (MRI) as a neuroimaging approach in the development of novel treatments for Alzheimer&#x02019;s disease. These considerations were generated in a roundtable at a recent Wellcome Trust meeting that included experts from academia and industry. It was agreed that MRI, either structural or functional, could be used as a diagnostic, for assessing worsening of disease status, for monitoring vascular pathology, and for stratifying clinical trial populations. It was agreed also that MRI implementation is in its infancy, requiring more evidence of association with the disease states, test-retest data, better standardization across multiple clinical sites, and application in multimodal approaches which include other imaging technologies, such as positron emission tomography, electroencephalography, and magnetoencephalography.</p></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>This article is the result of a roundtable held at the Wellcome Trust in the context of the meeting 'Biomarkers for Brain Disorders: Challenges and Opportunities&#x02019; in February 2013. The focus was on the relevance of neuroimaging biomarkers in the development of novel treatment in Alzheimer&#x02019;s disease (AD), with a particular focus on magnetic resonance imaging (MRI). AD is the most common form of senile dementia associated with cognitive decline, regional brain hypometabolism/atrophia, &#x003b2;-amyloid plaque deposition, accumulation of phosphorylated tau-containing neurofilament tangles (NFTs), vascular pathology, and neuroinflammation, and the diagnostic criteria of AD were recently amended [<xref ref-type="bibr" rid="B1">1</xref>]. Based on the experience of current precompetitive consortia such as the Alzheimer Disease Neuroimaging Initiative (ADNI) [<xref ref-type="bibr" rid="B2">2</xref>], the Innovative Medicine Initiative Pharma-Cog [<xref ref-type="bibr" rid="B3">3</xref>], or the Dominant Inherited Alzheimer Network [<xref ref-type="bibr" rid="B4">4</xref>], the general consensus was that MRI has great potential for improving novel drug development but is not a mature biomarker yet. As for other biomarkers, the current applications of neuroimaging include assistance in (a) the diagnosis of dementia, (b) the selection of subjects for enrollment in clinical trials or for stratification, (c) the tracking of disease progression, (d) providing evidence for target engagement for new therapeutic agents, and (e) providing evidence of disease-modifying effects (that is, normalization of a pathologic signal in association with clinical improvement (surrogate marker)). The MRI literature is partially supportive for the first three applications, whereas the database for the last two applications is still growing [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. The present article should not be seen as an exhaustive review of neuroimaging in AD research (as shown in [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]) but as an introduction to the uneven status of advancement of MRI technology for drug development.</p></sec><sec><title>A practical question</title><p>Developing a new drug is an evidence-based exercise. Collecting evidence relevant for decision-making to support the development of a novel chemical entity (NCE) requires investment in methodologies that are reliable, valid, and clinically relevant. In other words, we should answer the question: is it worthwhile to include a neuroimaging assessment in a clinical trial for a novel treatment in AD? If the method has regulatory approval, the inclusion in a clinical trial is generally supported. If not, the quality of the scientific data, the simplicity in execution, the reliability in multi-center assessment, and a reasonable cost would drive the decision for including imaging endpoints. In this case, expectations about trial outcome should be adjusted since the imaging measurements may deliver exploratory data whose real value will be appreciated only when combined with data coming from other research groups, possibly organized within precompetitive consortia (for example, ADNI). Remarkably, only a limited number of imaging biomarkers are endorsed by regulatory agencies (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). A series of methodological challenges are still facing the neuroimaging scientific community. The most important are (a) the interpretation of the biological meaning of the various neuroimaging measurements and their relationship with disease severity, (b) the test-retest reliability, and (c) the proper implementation into multi-center clinical trials. Hence, one of the main goals of the scientific community should be to provide answers to these questions and contribute to the regulatory approval of the neuroimaging methods.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Evidentiary table showing different imaging modalities implemented in AD research with relevant information</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="left"><bold>Patient population</bold></th><th align="left"><bold>Current use. (Potential clinical use)</bold></th><th align="left"><bold>Cost; feasibility. Burden</bold></th><th align="left"><bold>Biological and multi-center validation</bold></th><th align="left"><bold>Limitation</bold></th><th align="left"><bold>Regulatory status</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">FDG PET<hr/></td><td align="left" valign="bottom">MCI, AD, and other dementias<hr/></td><td align="left" valign="bottom">Diagnostic; stratification [<xref ref-type="bibr" rid="B10">10</xref>]; provide support to therapeutic clinic effects [<xref ref-type="bibr" rid="B11">11</xref>]. (Disease progression.)<hr/></td><td align="left" valign="bottom">High cost; - Feasible. - IV infusion radioactive agent needed.<hr/></td><td align="left" valign="bottom">Biological post-mortem data. Guidelines for single- and multi-site use, vendor-specific protocols. Standardized for multi-center trials. High validity [<xref ref-type="bibr" rid="B12">12</xref>].<hr/></td><td align="left" valign="bottom">Signal affected by inflammation and ischemia or behavior state [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B13">13</xref>]; misdiagnosis reported [<xref ref-type="bibr" rid="B14">14</xref>].<hr/></td><td align="left" valign="bottom">Indicated for differential diagnosis of dementia (FDA and EMA) in 2004. No regulatory qualification for use in early AD at this time.<hr/></td></tr><tr><td align="left" valign="bottom">Amyloid-&#x003b2; PET<hr/></td><td align="left" valign="bottom">MCI, AD, and other dementias<hr/></td><td align="left" valign="bottom">Diagnostic: AD exclusion; stratification; target engagement [<xref ref-type="bibr" rid="B15">15</xref>].<hr/></td><td align="left" valign="bottom">High cost; - Difficult. - IV infusion radioactive agent needed.<hr/></td><td align="left" valign="bottom">Biological post-mortem data [<xref ref-type="bibr" rid="B16">16</xref>]. Guidelines for single- and multi-site use, vendor-specific protocols. Standardization for multi-center trials partially achieved [<xref ref-type="bibr" rid="B12">12</xref>].<hr/></td><td align="left" valign="bottom">Cases of normal subjects with high amyloid-&#x003b2; and cases of subjects with dementia with low amyloid-&#x003b2;. Detection threshold to be validated [<xref ref-type="bibr" rid="B8">8</xref>].<hr/></td><td align="left" valign="bottom">Indicated for differential diagnosis of dementia in 2012 (FDA and EMA). Qualified as baseline measure for selecting patients for trials in pre-dementia and mild-moderate AD (EMA). Regulatory guidance for use in research and drug development.<hr/></td></tr><tr><td align="left" valign="bottom">Volumetric MRI<hr/></td><td align="left" valign="bottom">MCI, AD<hr/></td><td align="left" valign="bottom">Diagnostic [<xref ref-type="bibr" rid="B10">10</xref>]; stratification using hippocampal volume [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. (Disease progression; provide support to therapeutic clinic effects.)<hr/></td><td align="left" valign="bottom">Low cost; - Easy. Burden: no pacemaker carriers; claustrophobic reaction.<hr/></td><td align="left" valign="bottom">SOPs for single and multi-site; vendor-specific protocols. Standardization for multi-center trials partially achieved [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B9">9</xref>].<hr/></td><td align="left" valign="bottom">Lack molecular specificity. Direct data on hippocampal histopathology. Loss of volume as non-specific atrophy [<xref ref-type="bibr" rid="B9">9</xref>]. Patterns overlap with non-AD disease or in advanced aging.<hr/></td><td align="left" valign="bottom">Hippocampal volume qualified as baseline measure for selecting patients for trials in pre-dementia AD/MCI through EMA. Hippocampal volume qualification for patient stratification in MCI/AD through CAMD/FDA in progress.<hr/></td></tr><tr><td align="left" valign="bottom">ARIA MRI<hr/></td><td align="left" valign="bottom">MCI, AD<hr/></td><td align="left" valign="bottom">Safety signal; vascular integrity; inflammation [<xref ref-type="bibr" rid="B14">14</xref>].<hr/></td><td align="left" valign="bottom">Low cost; - Easy. Burden: no pacemaker carriers; claustrophobic reaction.<hr/></td><td align="left" valign="bottom">SOPs for single and multi-site; vendor-specific protocols. Standardization for multi-center trials achieved [<xref ref-type="bibr" rid="B19">19</xref>].<hr/></td><td align="left" valign="bottom">Occurrence of spontaneous ARIA in elderly unknown. False positive in untreated APP duplication case.<hr/></td><td align="left" valign="bottom">Requirement of monitoring (several MRI scans) during trials with amyloid-&#x003b2;-lowering agents (FDA and EMA).<hr/></td></tr><tr><td align="left" valign="bottom">DTI tracto-graphy<hr/></td><td align="left" valign="bottom">MCI, AD, non-clinical at genetic risk subject<hr/></td><td align="left" valign="bottom">Diagnostic [<xref ref-type="bibr" rid="B20">20</xref>]; stratification; disease progression. (Provide support to therapeutic clinic effects.)<hr/></td><td align="left" valign="bottom">Low cost; - Easy. Burden: no pacemaker carriers; claustrophobic reaction.<hr/></td><td align="left" valign="bottom">Biological validation in progress [<xref ref-type="bibr" rid="B21">21</xref>]. SOPs for single and multi-site; vendor-specific test protocols; standardization for multi-center trials in progress [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>].<hr/></td><td align="left" valign="bottom">Head motion artifacts; partial volume effects. Limited direct data on histopathology. Few multimodal relationships established.<hr/></td><td align="left" valign="bottom">No regulatory guidelines<hr/></td></tr><tr><td align="left" valign="bottom">Resting-state fMRI<hr/></td><td align="left" valign="bottom">MCI, AD, non-clinical at genetic risk subject<hr/></td><td align="left" valign="bottom">(Provide support to therapeutic clinic effect [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Stratification [<xref ref-type="bibr" rid="B26">26</xref>]; disease progression [<xref ref-type="bibr" rid="B7">7</xref>].)<hr/></td><td align="left" valign="bottom">Low cost; - Easy. Burden: no pacemaker carriers; claustrophobic reaction.<hr/></td><td align="left" valign="bottom">Various SOPs for BOLD in single- [<xref ref-type="bibr" rid="B27">27</xref>] and multi-center; ASL in single center [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Test-retest done [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Standardization for multi-center trials in progress [<xref ref-type="bibr" rid="B26">26</xref>].<hr/></td><td align="left" valign="bottom">Head motion artifacts; unclear biology; few data in histopathology. Preliminary data longitudinal and multimodal data available [<xref ref-type="bibr" rid="B7">7</xref>].<hr/></td><td align="left" valign="bottom">No regulatory guidelines<hr/></td></tr><tr><td align="left">Memory task - fMRI</td><td align="left">MCI, AD, non-clinical at genetic risk subject</td><td align="left">(Provide support to therapeutic clinic effect. Stratification [<xref ref-type="bibr" rid="B24">24</xref>]; disease progression [<xref ref-type="bibr" rid="B30">30</xref>].)</td><td align="left">Middle cost; - Complex. Burden: no pacemaker; claustrophobic reaction.</td><td align="left">Various SOPs for single center [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. Vendor-specific test protocols. No standard for multi-center trials. Test-retest not always available [<xref ref-type="bibr" rid="B33">33</xref>].</td><td align="left">Head motion artifacts; difficult implementation in cognitively impaired subject Longitudinal data available in part; incomplete reliability data [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B34">34</xref>].</td><td align="left">No regulatory guidelines</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer&#x02019;s disease; APP, amyloid precursor protein; ARIA, amyloid-related imaging abnormality; ASL, arterial spin labeling; BOLD, brain oxygen level-dependent; CAMD, coalition against major diseases; DTI, diffusion tensor imaging; EMA, European Medicines Agency; FDA, US Food and Drug Administration; FDG, fluoro-2-deoxy-D-glucose; fMRI, functional magnetic resonance imaging; IV, intravenous; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; PET, positron emission tomography; SOP, standard operating procedure.</p></table-wrap-foot></table-wrap></sec><sec><title>Neuroimaging in Alzheimer&#x02019;s disease: the legacy of positron emission tomography</title><p>Different neuroimaging modalities are at different stages of maturity regarding implementation in AD research. For example, for more than two decades, molecular neuroimaging assessed with positron emission tomography (PET), aimed to investigate key neurochemical processes at work in AD, has been used with a certain success to assist the diagnostic process in AD research [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. PET with [<xref ref-type="bibr" rid="B35">35</xref>]-<sup>18</sup>Fluoro-2-deoxy-D-glucose (FDG) used to map the cerebral metabolic rate of glucose was the first imaging methodology to receive regulatory approval for the diagnostic evaluation of dementia [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. The extent and severity of glucose hypometabolism have been reported to be predictive of conversion to AD in prodromal AD patients, and to correlate with cognitive impairment in prodromal and probable AD [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. However, for longitudinal use, careful control and standardization of acquisition are necessary. In fact, as a measure of brain activity, FDG PET is susceptible to biological variability due to normal aging, current state of arousal level, local inflammation, and other non-neuronal sources of metabolic changes, possibly resulting in misdiagnosis [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>].</p><p>PET-mediated visualization of the amyloid plaques in the brain was obtained by using amyloid-&#x003b2;-selective radioligands, at first with the Pittsburgh compound B (11C-PiB) and later with the <sup>18</sup>&#x02009;F-labeled tracers (for example, florbetapir, flutemetamol, and florbetaben) [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. Since 2011, several of these tracers received regulatory approval to assist in the diagnosis of dementia (in particular, for ruling out AD in favor of other forms of dementia when the amyloid-&#x003b2; signal was absent in the presence of cognitive impairment, in line with the revised Research Diagnostic Criteria for AD) [<xref ref-type="bibr" rid="B1">1</xref>]. However, since elevated amyloid load was described in up to 15% of non-demented subjects with age-adjusted normal cognitive profile, it is unclear whether this represents an early marker for individuals that will develop the disease soon or normal variations of a biological parameter with loose association with the disease [<xref ref-type="bibr" rid="B35">35</xref>]. More recently, the abundant NFT pathology, another hallmark of AD, has been targeted with the initial development of two novel PET ligands in clinical exploration: 18&#x000a0;F-T-807 and 11C-PBB-3 [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>]. It is notable that both amyloid-&#x003b2; peptides and phosphorylated tau levels can be measured biochemically in the cerebrospinal fluid and are validated biomarkers in AD research [<xref ref-type="bibr" rid="B40">40</xref>], questioning the need for the more expensive neuroimaging.</p><p>Amyloid-&#x003b2; PET recently qualified for the European regulatory agency (European Medicines Agency, or EMA) as a biomarker for population enrichment of clinical trials with prodromal and mild-moderate AD subjects (EMA/CHMP/SAWP/893622/2011 and EMA/CHMP/SAWP/892998/2011). Amyloid-&#x003b2;-selective radioligands were also used to provide evidence of target engagement for NCE aimed at amyloid-&#x003b2; plaques (that is, bapineuzumab [<xref ref-type="bibr" rid="B19">19</xref>] and gantenerumab [<xref ref-type="bibr" rid="B15">15</xref>]). These studies showed a significant dose-dependent reduction of the amyloid-&#x003b2; PET signal over a period of several months of treatment. However, data available from large clinical trials indicate that changes of amyloid-&#x003b2; signal were not associated with changes of disease clinical severity in patients with AD [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B41">41</xref>] and, to date, should not be used as a surrogate marker for efficacy. A final note: the implementation of PET requires exposure to radioactivity that limits the repeated use in the same individuals as well as specialized centers and significant investment. Therefore, while PET can provide unique and useful information, these limitations challenge use in large clinical trials and even in community-based health care. In fact, for these reasons, PET is often implemented in a sub-study of a larger multi-center clinical trial, targeting a sub-population of the whole study.</p></sec><sec><title>Magnetic resonance imaging implementation in Alzheimer&#x02019;s disease research</title><p>MRI-related techniques are gaining increasing interest since their use does not require radioactivity exposure and they can be easily repeated in the same subjects with no harm, are relatively inexpensive, and can be operated with scanner machines available in almost any hospital [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. In clinical trials, MRI is commonly used as a radiologic diagnostic aid to exclude individuals with incidental brain pathologies. The evidence supporting their use as specific biomarkers for AD is still limited (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). We briefly describe the most promising use of MRI.</p><sec><title>Structural magnetic resonance imaging</title><p>Structural MRI is an imaging modality that describes the shape, size, and integrity of gray and white matter structures in the brain; it is highly sensitive to the atrophic and vascular changes that occur in the AD central nervous system [<xref ref-type="bibr" rid="B6">6</xref>].</p><sec><title>Volumetric magnetic resonance imaging</title><p>Volumetric MRI is based on data collected by using T1-weighted sequences that are quantified by using both manual and automatic image analysis. Whereas harmonization of manually segmented hippocampus is in progress [<xref ref-type="bibr" rid="B17">17</xref>], automated image analysis software (NeuroQuant; CorTechs Labs Inc., San Diego, CA, USA) was recently approved as a medical device to provide an aid in dementia diagnosis [<xref ref-type="bibr" rid="B18">18</xref>].</p><p>Volumetric MRI collected longitudinally at two or more time points is the most mature imaging biomarker of disease progression in AD [<xref ref-type="bibr" rid="B6">6</xref>], recently supported by multimodal evidence using FDG [<xref ref-type="bibr" rid="B36">36</xref>]. Progression of atrophy in the whole brain and in areas targeted by AD (medial temporal lobe, temporoparietal, and restrosplenial cortex) represents a reliable marker of the neurodegenerative process underlying clinical symptoms, more robust than amyloidosis alone. Hippocampal volumetric MRI has been validated versus pathologic post-mortem markers such as neuronal loss and Braak stages [<xref ref-type="bibr" rid="B42">42</xref>]. Hippocampal volumetric MRI is qualified by EMA as a biomarker for enrichment of pre-dementia AD trials [<xref ref-type="bibr" rid="B17">17</xref>], these prodromal subjects having already lost about 20% of its volume. Progression of whole-brain and hippocampal atrophy has been shown to correlate closely with clinical worsening in patients with AD [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Notably, an unexpected paradoxical finding was reported in anti-amyloid immunotherapeutic studies in AD [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B43">43</xref>], showing a reduced volume in hippocampus, whole brain, and cortex. These results are calling for a re-evaluation of the neurobiological interpretation of the volumetric MRI reduction. The short-term reduction of brain volume has been hypothesized to result from changes in fluid balance or amyloid plaque removal rather than a sustained increase in rate of atrophy. Multimodal studies including FDG PET and functional MRI (fMRI) as well as post-mortem studies would eventually lead to a better understanding of the biological underpinning of this phenomenon.</p><p>Methodologically, accurate volumetric assessment requires standard operating procedures that include the know-how specific for the modality, acquisition parameters, and suitable training of the staff [<xref ref-type="bibr" rid="B5">5</xref>]. For this reason, strict standardization of acquisition and measurement is being undertaken for manual hippocampal volumetry by a European Alzheimer&#x02019;s Disease Consortium (EADC)-ADNI consortium under the auspices of the Alzheimer&#x02019;s Association [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. The EADC-ADNI standard operating procedures will be used to validate automated algorithms, such as FreeSurfer and Learning Embeddings Atlas Propagation. Other brain regions are under active investigation; for example, the entorhinal cortex showed performance similar to hippocampus using the Quarc analysis software (Quarc, Wedemark, Germany) [<xref ref-type="bibr" rid="B45">45</xref>]. According to this study, when these markers were used as primary endpoints, a sample size of about 100 subjects with AD would be sufficient to detect a 25% reduction of annual atrophy rate produced by a putative novel treatment [<xref ref-type="bibr" rid="B45">45</xref>]. This is at least threefold less than the sample size needed when using clinical scales such as the Alzheimer&#x02019;s Disease Assessment Scale-cognitive subscale as endpoints.</p></sec><sec><title>Vascular magnetic resonance imaging</title><p>The modality of T2-weighted/fluid inversion recovery is particularly useful to identify vasogenic edema and microhemorrhages, defined as the amyloid-related imaging abnormalities (ARIAs) in AD research [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. Regulatory authorities require their use in clinical trials implementing the &#x003b2;-amyloid-lowering drugs for safety reasons. For example, in two bapimezumab phase II trials, ARIAs occurred in 17% of patients with AD, 78% of whom did not report clinical correlates [<xref ref-type="bibr" rid="B19">19</xref>]. The occurrence of ARIAs seems to depend on the dose of the &#x003b2;-amyloid-lowering drug and on the presence of the apolipoprotein E4&#x003f5; genotype, which is characterized by a significantly higher &#x003b2;-amyloid burden [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. A rating scale was recently proposed [<xref ref-type="bibr" rid="B46">46</xref>].</p></sec></sec><sec><title>Diffusion tensor imaging magnetic resonance imaging</title><p>Through the assessment of the random motion of water molecules in the tissue, diffusion tensor imaging (DTI) has provided new tools to the study of white matter alterations in AD brain mostly by assessing two parameters: the fractal anisotropy (FA) and the mean diffusivity (MD). FA is considered a marker of axonal integrity and myelinization, whereas MD represents the overall cellular integrity [<xref ref-type="bibr" rid="B47">47</xref>]. The combined use of DTI and volumetric MRI in the cingulated cortex was shown to increase the imaging-based classification of AD cases versus control with up to 91% accuracy [<xref ref-type="bibr" rid="B21">21</xref>]. Initially, DTI has been perceived as a technique with poor reproducibility and site/scanner dependency. Recent multi-center trials in Huntington&#x02019;s disease and AD seem to contradict this preoccupation, suggesting a low center-dependent bias and a real possible use as a surrogate endpoint [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>Functional magnetic resonance imaging</title><p>fMRI can be defined as a technology that provides statistical maps of brain activation [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Brain activation is indirectly obtained by measuring changes of regional microcirculation produced by local neural activity triggered by external stimuli, behavioral performance, or neuroactive drugs. Two kinds of magnetic resonance signals are generally measured: the blood oxygenation level-dependent (BOLD) and the arterial spin labeling (ASL) signals [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B48">48</xref>].</p><sec><title>Activation task functional magnetic resonance imaging procedures</title><p>Most brain activation maps obtained in patients with AD have been generated during memory tasks and using BOLD, showing reduced activity in hippocampus/medial temporal lobe and increased activity in prefrontal cortex while encoding new information [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Similar abnormalities, in particular decreases in the medial temporal lobe, were observed in subjects with prodromal AD/mild cognitive impairment (MCI) [<xref ref-type="bibr" rid="B48">48</xref>]. Intriguingly, increases were described in the early phase of the disease [<xref ref-type="bibr" rid="B32">32</xref>] and in asymptomatic individuals with genetic risk for AD [<xref ref-type="bibr" rid="B24">24</xref>]. This hyper-activation was interpreted as a possible compensatory mechanism at work within the networks whose structures were impaired, a pathologic marker of impending neural failure [<xref ref-type="bibr" rid="B9">9</xref>]. Whereas data on longitudinal test-retest were provided in single-center studies [<xref ref-type="bibr" rid="B33">33</xref>], fMRI activation tasks were very rarely used in multi-center studies, highlighting the need for further validation and standardization.</p><p>Logistically, the typical fMRI activation task is quite complex, requiring audio/visual support for stimuli presentation (for example, goggles) and performance recording (for example, joysticks), expert personnel, calibration procedures for each tasks, and proven invariance to repeated exposure (often not studied), therefore making their implementation difficult in multi-center trials or in routine use as a diagnostic in the community.</p></sec><sec><title>Task-free functional magnetic resonance imaging procedures</title><p>More recently, resting-state fMRI (rs-fMRI) was introduced to collect signals while the subject is not performing any particular tasks [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. This task-free approach is ideal in poorly collaborative subjects, such as severely demented patients, and does not require a specialized staff. rs-fMRI is based on the collection of time series of whole-brain MRI signal fluctuations (generally BOLD) measured in each brain voxel while the subject is at rest [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. The similarity between time series in different brain areas can be assessed mathematically as correlation matrices, indicating functional connectivity [<xref ref-type="bibr" rid="B29">29</xref>]. Consistent patterns of connectivity at resting state were reported by several authors, evaluated in test-retest protocol, and related to specific electrophysiological signatures in topologically restricted brain areas, exemplified by the 'default mode&#x02019; network (DMN) [<xref ref-type="bibr" rid="B34">34</xref>]. In AD, impaired DMN has been reported, including longitudinal data that showed a correlation with clinical symptom worsening [<xref ref-type="bibr" rid="B6">6</xref>]. Interestingly, rs-fMRI studies in non-demented adults carrying a familial AD gene mutation showed hyper-connectivity in the dorsolateral prefrontal cortex and decreased connectivity in the precuneus [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. rs-fMRI is also a stronger classifier than memory task-associated fMRI when used in non-demented adults carrying a familial AD mutation [<xref ref-type="bibr" rid="B27">27</xref>]. Interestingly, changes of connectivity in the DMN of subjects with AD were observed following chronic treatment with memantine [<xref ref-type="bibr" rid="B49">49</xref>] and donepezil [<xref ref-type="bibr" rid="B25">25</xref>].</p></sec><sec><title>Arterial spin labeling</title><p>In the last few years, ASL has attracted the attention of various research groups [<xref ref-type="bibr" rid="B7">7</xref>]. ASL MRI was validated versus perfusion PET showing convergent information about regional cerebral blood flow of diagnostic relevance, with higher resolution and no exposure to radioactive tracers [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Evidence of hypoperfusion in AD and prodromal AD/MCI conditions was confirmed and extended to a series of other brain areas, and the initial evidence is that ASL may have properties of diagnostics and markers of disease severity [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B50">50</xref>]. ASL measurements appear less variable than BOLD in test-retest trials in a single center. Unfortunately, to date, it cannot be easily implemented in multi-center trials since different vendors of MRI scanners have implemented different sequences of acquisition, therefore hindering comparison among sites with different MRI scanners.</p></sec></sec></sec><sec><title>Conclusions and future directions</title><p>There is a role for MRI as a biomarker in clinical trials aimed at the development of new treatment for AD. However, a series of challenges is still looming, in particular for fMRI. Among them, we have identified reliability and repeatability for specific tests, standardization across multiple sites, development of validated automated quantification tools, implementation of multiple modalities (for example, merging PET and rs-fMRI), cost optimization, and selection of the most accurate and efficient diagnostic combination of markers, including fluid-based biomarker modalities. Most of these challenges are tackled in the context of large consortia involving collaborations between academia and industry as well as in some contract research organizations and technology-oriented academic centers. The delivery of this research is of relevance for building confidence in imaging biomarkers: at present, with the exception of safety assessment of ARIA signals, the implementation of MRI in pharmaceutical clinical trials is still seen as exploratory rather than decision-making.</p></sec><sec><title>Abbreviations</title><p>AD: Alzheimer&#x02019;s disease; ADNI: Alzheimer Disease Neuroimaging Initiative; ARIA: Amyloid-related imaging abnormality; ASL: Arterial spin labeling; BOLD: Blood oxygen level-dependent; DMN: Default mode network; DTI: Diffusion tensor imaging; EADC: European Alzheimer&#x02019;s Disease Consortium; EMA: European Medicines Agency; FA: Fractal anisotropy; FDG: Fluoro-2-deoxy-D-glucose; fMRI: Functional magnetic resonance imaging; MCI: Mild cognitive impairment; MD: Mean diffusivity; MRI: Magnetic resonance imaging; NCE: Novel chemical entity; NFT: Neurofibrillary tangle; PET: Positron emission tomography; rs-fMRI: Resting-state functional magnetic resonance imaging.</p></sec><sec><title>Competing interests</title><p>AL is an employee of GlaxoSmithKline (Brentford, UK). MES is an employee of Janssen Pharmaceutica (Beerse, Belgium). AJ is an employee of Atlantic Biomarkers, LLC (Gainesville, FL, USA). EMP is an employee of F. Hoffmann-La Roche AG (Basel, Switzerland). DH is an employee of IXICO (London, UK). GBF has served on advisory boards for Eli Lilly and Company (Indianapolis, IN, USA), Bristol-Myers Squibb (New York, NY, USA), Bayer (Leverkusen, Germany), Lundbeck (Copenhagen, Denmark), Elan (Dublin, Ireland), AstraZeneca (London, UK), Pfizer Inc (New York, NY, USA), TauRx (Aberdeen, UK), Wyeth (Philadelphia, PA, USA), GE (Fairfield, CT, USA), and Baxter (Deerfield, IL, USA); is a member of the editorial boards of <italic>Lancet Neurology</italic>, <italic>Aging Clinical &#x00026; Experimental Research</italic>, <italic>Alzheimer&#x02019;s Diseases &#x00026; Associated Disorders</italic>, and <italic>Neurodegenerative Diseases</italic>; is the imaging section editor of <italic>Neurobiology of Aging</italic>; has received grants from Wyeth International, Lilly International, Lundbeck Italia, GE International, Avid/Lilly, Roche, and the Alzheimer&#x02019;s Association; and in the past 2&#x000a0;years has received lecture fees to speak at the invitation of Lundbeck. WZP has served on advisory boards for Amgen (Thousand Oaks, CA, USA), Allelix (Mississauga, ON, Canada), Ironwood (Cambridge, MA, USA), Eli Lilly and Company, Taisho (Tokyo, Japan), Takeda (Osaka, Japan), and Teva (Petah Tikva, Israel) in the last 12&#x000a0;months. SM declares that she has no competing interests.</p></sec></body><back><sec><title>Acknowledgments</title><p>We thank the participants of the Wellcome Trust meeting on Brain Disorders for discussion, the Wellcome Trust for support, and Treasan Creavin and Lucy Criddle for their help in organizing this venue.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>McKhann</surname><given-names>GM</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Kawas</surname><given-names>CH</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Koroshetz</surname><given-names>WJ</given-names></name><name><surname>Manly</surname><given-names>JJ</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Mohs</surname><given-names>RC</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Thies</surname><given-names>B</given-names></name><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name><article-title>The diagnosis of dementia due to Alzheimer&#x02019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x02019;s Association workgroups on diagnostic guidelines for Alzheimer&#x02019;s disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmid">21514250</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Veitch</surname><given-names>DP</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Beckett</surname><given-names>LA</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Harvey</surname><given-names>D</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Jagust</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name><name><surname>Schmidt</surname><given-names>ME</given-names></name><name><surname>Shaw</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Siuciak</surname><given-names>JA</given-names></name><name><surname>Soares</surname><given-names>H</given-names></name><name><surname>Toga</surname><given-names>AW</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><collab>Alzheimer&#x02019;s Disease Neuroimaging Initiative</collab><article-title>The Alzheimer&#x02019;s Disease Neuroimaging Initiative: a review of papers published since its inception</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><fpage>e111</fpage><lpage>e194</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2013.05.1769</pub-id><pub-id pub-id-type="pmid">23932184</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="other"><source>Innovative Medicines Initiative homepage</source><comment>[<ext-link ext-link-type="uri" xlink:href="http://www.imi.europa.eu/content/pharma-cog">http://www.imi.europa.eu/content/pharma-cog</ext-link>]</comment></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Moulder</surname><given-names>KL</given-names></name><name><surname>Snider</surname><given-names>BJ</given-names></name><name><surname>Mills</surname><given-names>SL</given-names></name><name><surname>Buckles</surname><given-names>VD</given-names></name><name><surname>Santacruz</surname><given-names>AM</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><article-title>Dominantly Inherited Alzheimer Network: facilitating research and clinical trials</article-title><source>Alzheimers Res Ther</source><year>2013</year><volume>5</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/alzrt213</pub-id><pub-id pub-id-type="pmid">24131566</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Bocchetta</surname><given-names>M</given-names></name><name><surname>Ch&#x000e9;telat</surname><given-names>G</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name><name><surname>de Leon</surname><given-names>MJ</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Herholz</surname><given-names>K</given-names></name><name><surname>Nordberg</surname><given-names>A</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Rowe</surname><given-names>CC</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Thies</surname><given-names>W</given-names></name><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Pasqualetti</surname><given-names>P</given-names></name><name><surname>Decarli</surname><given-names>C</given-names></name><collab>ISTAART&#x02019;s NeuroImaging Professional Interest Area</collab><article-title>Imaging markers for Alzheimer disease: which vs how</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>487</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31829d86e8</pub-id><pub-id pub-id-type="pmid">23897875</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Thompson</surname><given-names>PM</given-names></name><article-title>The clinical use of structural MRI in Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2010</year><volume>6</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2009.215</pub-id><pub-id pub-id-type="pmid">20139996</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Damoiseaux</surname><given-names>JS</given-names></name><name><surname>Prater</surname><given-names>KE</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Greicius</surname><given-names>MD</given-names></name><article-title>Functional connectivity tracks clinical deterioration in Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2012</year><volume>33</volume><fpage>e19-30</fpage><pub-id pub-id-type="pmid">21840627</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Ashford</surname><given-names>JW</given-names></name><name><surname>Salehi</surname><given-names>A</given-names></name><name><surname>Furst</surname><given-names>A</given-names></name><name><surname>Bayley</surname><given-names>P</given-names></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Sabri</surname><given-names>O</given-names></name><name><surname>Adamson</surname><given-names>MM</given-names></name><name><surname>Coburn</surname><given-names>KL</given-names></name><name><surname>Olichney</surname><given-names>J</given-names></name><name><surname>Schuff</surname><given-names>N</given-names></name><name><surname>Spielman</surname><given-names>D</given-names></name><name><surname>Edland</surname><given-names>SD</given-names></name><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Rosen</surname><given-names>A</given-names></name><name><surname>Kennedy</surname><given-names>D</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><article-title>Imaging the Alzheimer brain</article-title><source>J Alzheimers Dis</source><year>2011</year><volume>26</volume><issue>Suppl 3</issue><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">21971448</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><article-title>Brain imaging in Alzheimer disease</article-title><source>Cold Spring Harb Perspect Med</source><year>2012</year><volume>2</volume><fpage>a006213</fpage><pub-id pub-id-type="pmid">22474610</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Foster</surname><given-names>NL</given-names></name><name><surname>Heidebrink</surname><given-names>JL</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Barbas</surname><given-names>NR</given-names></name><name><surname>DeCarli</surname><given-names>CS</given-names></name><name><surname>Turner</surname><given-names>RS</given-names></name><name><surname>Koeppe</surname><given-names>RA</given-names></name><name><surname>Higdon</surname><given-names>R</given-names></name><name><surname>Minoshima</surname><given-names>S</given-names></name><article-title>FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer&#x02019;s disease</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>2616</fpage><lpage>2635</lpage><pub-id pub-id-type="doi">10.1093/brain/awm177</pub-id><pub-id pub-id-type="pmid">17704526</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Reiman</surname><given-names>EM</given-names></name><collab>Alzheimer&#x02019;s Disease Biomarkers Working Group for the Alliance for Aging R</collab><article-title>Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer&#x02019;s disease-modifying treatments</article-title><source>Neurobiol Aging</source><year>2011</year><volume>32</volume><issue>Suppl 1</issue><fpage>S44</fpage><lpage>S47</lpage><pub-id pub-id-type="pmid">21983241</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Yamane</surname><given-names>T</given-names></name><name><surname>Ikari</surname><given-names>Y</given-names></name><name><surname>Nishio</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Silverman</surname><given-names>DH</given-names></name><name><surname>Senda</surname><given-names>M</given-names></name><name><surname>Asada</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Sugishita</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><collab>J-ADNI Study Group</collab><article-title>Visual-statistical interpretation of 18&#x000a0;F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation</article-title><source>AJNR Am J Neuroradiol</source><year>2014</year><volume>35</volume><fpage>244</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A3665</pub-id><pub-id pub-id-type="pmid">23907243</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Gross-Glenn</surname><given-names>K</given-names></name><name><surname>Barker</surname><given-names>WW</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Apicella</surname><given-names>A</given-names></name><name><surname>Loewenstein</surname><given-names>D</given-names></name><name><surname>Boothe</surname><given-names>T</given-names></name><article-title>Behavioral activation and the variability of cerebral glucose metabolic measurements</article-title><source>J Cereb Blood Flow Metab</source><year>1987</year><volume>7</volume><fpage>266</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1987.62</pub-id><pub-id pub-id-type="pmid">3495545</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Shipley</surname><given-names>SM</given-names></name><name><surname>Frederick</surname><given-names>MC</given-names></name><name><surname>Filley</surname><given-names>CM</given-names></name><name><surname>Kluger</surname><given-names>BM</given-names></name><article-title>Potential for misdiagnosis in community-acquired PET scans for dementia</article-title><source>Neurol Clin Pract</source><year>2013</year><volume>3</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1212/CPJ.0b013e318296f2df</pub-id><pub-id pub-id-type="pmid">24195019</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Ostrowitzki</surname><given-names>S</given-names></name><name><surname>Deptula</surname><given-names>D</given-names></name><name><surname>Thurfjell</surname><given-names>L</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Bohrmann</surname><given-names>B</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Ashford</surname><given-names>E</given-names></name><name><surname>Yoo</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>ZX</given-names></name><name><surname>Loetscher</surname><given-names>H</given-names></name><name><surname>Santarelli</surname><given-names>L</given-names></name><article-title>Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.1538</pub-id><pub-id pub-id-type="pmid">21987394</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Pontecorvo</surname><given-names>MJ</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Bedell</surname><given-names>BJ</given-names></name><name><surname>Coleman</surname><given-names>RE</given-names></name><name><surname>Doraiswamy</surname><given-names>PM</given-names></name><name><surname>Fleisher</surname><given-names>AS</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Sadowsky</surname><given-names>CH</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Arora</surname><given-names>A</given-names></name><name><surname>Carpenter</surname><given-names>AP</given-names></name><name><surname>Flitter</surname><given-names>ML</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Krautkramer</surname><given-names>MJ</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Mintun</surname><given-names>MA</given-names></name><name><surname>Skovronsky</surname><given-names>DM</given-names></name><collab>AV-45-A16 Study Group</collab><article-title>Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study</article-title><source>Lancet Neurol</source><year>2012</year><volume>11</volume><fpage>669</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70142-4</pub-id><pub-id pub-id-type="pmid">22749065</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><article-title>Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>171</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2010.06.007</pub-id><pub-id pub-id-type="pmid">21414554</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>McEvoy</surname><given-names>LK</given-names></name><name><surname>Brewer</surname><given-names>JB</given-names></name><article-title>Quantitative structural MRI for early detection of Alzheimer&#x02019;s disease</article-title><source>Expert Rev Neurother</source><year>2010</year><volume>10</volume><fpage>1675</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1586/ern.10.162</pub-id><pub-id pub-id-type="pmid">20977326</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Tampieri</surname><given-names>D</given-names></name><name><surname>Barakos</surname><given-names>J</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Sabbagh</surname><given-names>M</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Arrighi</surname><given-names>HM</given-names></name><name><surname>Morris</surname><given-names>KA</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Gregg</surname><given-names>KM</given-names></name><name><surname>Brashear</surname><given-names>HR</given-names></name><name><surname>Kinney</surname><given-names>GG</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><article-title>Amyloid-related imaging abnormalities in patients with Alzheimer&#x02019;s disease treated with bapineuzumab: a retrospective analysis</article-title><source>Lancet Neurol</source><year>2012</year><volume>11</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70015-7</pub-id><pub-id pub-id-type="pmid">22305802</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Binnewijzend</surname><given-names>MA</given-names></name><name><surname>Kuijer</surname><given-names>JP</given-names></name><name><surname>Benedictus</surname><given-names>MR</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Wink</surname><given-names>AM</given-names></name><name><surname>Wattjes</surname><given-names>MP</given-names></name><name><surname>van Berckel</surname><given-names>BN</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><article-title>Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity</article-title><source>Radiology</source><year>2013</year><volume>267</volume><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1148/radiol.12120928</pub-id><pub-id pub-id-type="pmid">23238159</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Gold</surname><given-names>BT</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Powell</surname><given-names>DK</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><article-title>Multimodal imaging evidence for axonal and myelin deterioration in amnestic mild cognitive impairment</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>31</volume><issue>Suppl 3</issue><fpage>S19</fpage><lpage>S31</lpage><pub-id pub-id-type="pmid">22460327</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>M&#x000fc;ller</surname><given-names>HP</given-names></name><name><surname>Gr&#x000f6;n</surname><given-names>G</given-names></name><name><surname>Sprengelmeyer</surname><given-names>R</given-names></name><name><surname>Kassubek</surname><given-names>J</given-names></name><name><surname>Ludolph</surname><given-names>AC</given-names></name><name><surname>Hobbs</surname><given-names>N</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><name><surname>Roos</surname><given-names>RA</given-names></name><name><surname>Duerr</surname><given-names>A</given-names></name><name><surname>Tabrizi</surname><given-names>SJ</given-names></name><name><surname>Landwehrmeyer</surname><given-names>GB</given-names></name><name><surname>S&#x000fc;ssmuth</surname><given-names>SD</given-names></name><article-title>Evaluating multicenter DTI data in Huntington&#x02019;s disease on site specific effects: an ex post facto approach</article-title><source>NeuroImage Clinical</source><year>2013</year><volume>2</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">24179771</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Dyrba</surname><given-names>M</given-names></name><name><surname>Ewers</surname><given-names>M</given-names></name><name><surname>Wegrzyn</surname><given-names>M</given-names></name><name><surname>Kilimann</surname><given-names>I</given-names></name><name><surname>Plant</surname><given-names>C</given-names></name><name><surname>Oswald</surname><given-names>A</given-names></name><name><surname>Meindl</surname><given-names>T</given-names></name><name><surname>Pievani</surname><given-names>M</given-names></name><name><surname>Bokde</surname><given-names>AL</given-names></name><name><surname>Fellgiebel</surname><given-names>A</given-names></name><name><surname>Filippi</surname><given-names>M</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Kl&#x000f6;ppel</surname><given-names>S</given-names></name><name><surname>Hauenstein</surname><given-names>K</given-names></name><name><surname>Kirste</surname><given-names>T</given-names></name><name><surname>Teipel</surname><given-names>SJ</given-names></name><collab>EDSD study group</collab><article-title>Robust automated detection of microstructural white matter degeneration in Alzheimer&#x02019;s disease using machine learning classification of multicenter DTI data</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e64925</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0064925</pub-id><pub-id pub-id-type="pmid">23741425</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Filippini</surname><given-names>N</given-names></name><name><surname>MacIntosh</surname><given-names>BJ</given-names></name><name><surname>Hough</surname><given-names>MG</given-names></name><name><surname>Goodwin</surname><given-names>GM</given-names></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><name><surname>Beckmann</surname><given-names>CF</given-names></name><name><surname>Mackay</surname><given-names>CE</given-names></name><article-title>Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>7209</fpage><lpage>7214</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811879106</pub-id><pub-id pub-id-type="pmid">19357304</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Antuono</surname><given-names>PG</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>JL</given-names></name><name><surname>Ward</surname><given-names>BD</given-names></name><name><surname>Franczak</surname><given-names>MB</given-names></name><name><surname>Goveas</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>SJ</given-names></name><article-title>Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer&#x02019;s disease after 12-week donepezil treatment</article-title><source>Neuroimage</source><year>2012</year><volume>60</volume><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.12.077</pub-id><pub-id pub-id-type="pmid">22245641</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Chhatwal</surname><given-names>JP</given-names></name><name><surname>Schultz</surname><given-names>AP</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Benzinger</surname><given-names>TL</given-names></name><name><surname>Jack</surname><given-names>C</given-names><suffix>Jr</suffix></name><name><surname>Ances</surname><given-names>BM</given-names></name><name><surname>Sullivan</surname><given-names>CA</given-names></name><name><surname>Salloway</surname><given-names>SP</given-names></name><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Koeppe</surname><given-names>RA</given-names></name><name><surname>Marcus</surname><given-names>DS</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name><name><surname>Correia</surname><given-names>S</given-names></name><name><surname>Schofield</surname><given-names>PR</given-names></name><name><surname>Rowe</surname><given-names>CC</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Brickman</surname><given-names>AM</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>McDade</surname><given-names>E</given-names></name><name><surname>Bateman</surname><given-names>R</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Xiong</surname><given-names>C</given-names></name><name><surname>Buckles</surname><given-names>VD</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name><article-title>Impaired default network functional connectivity in autosomal dominant Alzheimer disease</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>736</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a1aafe</pub-id><pub-id pub-id-type="pmid">23884042</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Fleisher</surname><given-names>AS</given-names></name><name><surname>Sherzai</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Langbaum</surname><given-names>JB</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Buxton</surname><given-names>RB</given-names></name><article-title>Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer&#x02019;s disease risk groups</article-title><source>Neuroimage</source><year>2009</year><volume>47</volume><fpage>1678</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.06.021</pub-id><pub-id pub-id-type="pmid">19539034</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Wolk</surname><given-names>DA</given-names></name><name><surname>Detre</surname><given-names>JA</given-names></name><article-title>Arterial spin labeling MRI: an emerging biomarker for Alzheimer&#x02019;s disease and other neurodegenerative conditions</article-title><source>Curr Opin Neurol</source><year>2012</year><volume>25</volume><fpage>421</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1097/WCO.0b013e328354ff0a</pub-id><pub-id pub-id-type="pmid">22610458</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Filippi</surname><given-names>M</given-names></name><name><surname>Agosta</surname><given-names>F</given-names></name><article-title>Structural and functional network connectivity breakdown in Alzheimer&#x02019;s disease studied with magnetic resonance imaging techniques</article-title><source>J Alzheimers Dis</source><year>2011</year><volume>24</volume><fpage>455</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">21297259</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Bates</surname><given-names>JF</given-names></name><name><surname>Chua</surname><given-names>EF</given-names></name><name><surname>Cocchiarella</surname><given-names>AJ</given-names></name><name><surname>Rentz</surname><given-names>DM</given-names></name><name><surname>Rosen</surname><given-names>BR</given-names></name><name><surname>Schacter</surname><given-names>DL</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><article-title>fMRI studies of associative encoding in young and elderly controls and mild Alzheimer&#x02019;s disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2003</year><volume>74</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1136/jnnp.74.1.44</pub-id><pub-id pub-id-type="pmid">12486265</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Sol&#x000e9;-Padull&#x000e9;s</surname><given-names>C</given-names></name><name><surname>Bartr&#x000e9;s-Faz</surname><given-names>D</given-names></name><name><surname>Junqu&#x000e9;</surname><given-names>C</given-names></name><name><surname>Vendrell</surname><given-names>P</given-names></name><name><surname>Rami</surname><given-names>L</given-names></name><name><surname>Clemente</surname><given-names>IC</given-names></name><name><surname>Bosch</surname><given-names>B</given-names></name><name><surname>Villar</surname><given-names>A</given-names></name><name><surname>Bargall&#x000f3;</surname><given-names>N</given-names></name><name><surname>Jurado</surname><given-names>MA</given-names></name><name><surname>Barrios</surname><given-names>M</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><article-title>Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2009</year><volume>30</volume><fpage>1114</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.10.008</pub-id><pub-id pub-id-type="pmid">18053618</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Celone</surname><given-names>KA</given-names></name><name><surname>Calhoun</surname><given-names>VD</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name><name><surname>Atri</surname><given-names>A</given-names></name><name><surname>Chua</surname><given-names>EF</given-names></name><name><surname>Miller</surname><given-names>SL</given-names></name><name><surname>DePeau</surname><given-names>K</given-names></name><name><surname>Rentz</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name><article-title>Alterations in memory networks in mild cognitive impairment and Alzheimer&#x02019;s disease: an independent component analysis</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>10222</fpage><lpage>10231</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2250-06.2006</pub-id><pub-id pub-id-type="pmid">17021177</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Atri</surname><given-names>A</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>JL</given-names></name><name><surname>Sreenivasan</surname><given-names>A</given-names></name><name><surname>Rastegar</surname><given-names>S</given-names></name><name><surname>Salisbury</surname><given-names>S</given-names></name><name><surname>DeLuca</surname><given-names>AN</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>KM</given-names></name><name><surname>LaViolette</surname><given-names>PS</given-names></name><name><surname>Rentz</surname><given-names>DM</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name><article-title>Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials</article-title><source>Arch Neurol</source><year>2011</year><volume>68</volume><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">21555634</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Raichle</surname><given-names>ME</given-names></name><name><surname>MacLeod</surname><given-names>AM</given-names></name><name><surname>Snyder</surname><given-names>AZ</given-names></name><name><surname>Powers</surname><given-names>WJ</given-names></name><name><surname>Gusnard</surname><given-names>DA</given-names></name><name><surname>Shulman</surname><given-names>GL</given-names></name><article-title>A default mode of brain function</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1073/pnas.98.2.676</pub-id><pub-id pub-id-type="pmid">11209064</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Mintun</surname><given-names>MA</given-names></name><name><surname>Larossa</surname><given-names>GN</given-names></name><name><surname>Sheline</surname><given-names>YI</given-names></name><name><surname>Dence</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Mach</surname><given-names>RH</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Mathis</surname><given-names>CA</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><article-title>[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>446</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000228230.26044.a4</pub-id><pub-id pub-id-type="pmid">16894106</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Dukart</surname><given-names>J</given-names></name><name><surname>Kherif</surname><given-names>F</given-names></name><name><surname>Mueller</surname><given-names>K</given-names></name><name><surname>Adaszewski</surname><given-names>S</given-names></name><name><surname>Schroeter</surname><given-names>ML</given-names></name><name><surname>Frackowiak</surname><given-names>RS</given-names></name><name><surname>Draganski</surname><given-names>B</given-names></name><collab>Alzheimer&#x02019;s Disease Neuroimaging I</collab><article-title>Generative FDG-PET and MRI model of aging and disease progression in Alzheimer&#x02019;s disease</article-title><source>PLoS Comput Biol</source><year>2013</year><volume>9</volume><fpage>e1002987</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002987</pub-id><pub-id pub-id-type="pmid">23592957</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Goodman</surname><given-names>MM</given-names></name><article-title>Fluorine-18 radiolabeled heterocycles as PET tracers for imaging beta-amyloid plaques in Alzheimer&#x02019;s disease</article-title><source>Curr Top Med Chem</source><year>2013</year><volume>13</volume><fpage>909</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.2174/1568026611313080004</pub-id><pub-id pub-id-type="pmid">23590167</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Wood</surname><given-names>H</given-names></name><article-title>Alzheimer disease: [C]PBB3 - a new PET ligand that identifies tau pathology in the brains of patients with AD</article-title><source>Nat Rev Neurol</source><year>2013</year><volume>9</volume><fpage>599</fpage><pub-id pub-id-type="doi">10.1038/nrneurol.2013.216</pub-id><pub-id pub-id-type="pmid">24145369</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Chien</surname><given-names>DT</given-names></name><name><surname>Bahri</surname><given-names>S</given-names></name><name><surname>Szardenings</surname><given-names>AK</given-names></name><name><surname>Walsh</surname><given-names>JC</given-names></name><name><surname>Mu</surname><given-names>F</given-names></name><name><surname>Su</surname><given-names>MY</given-names></name><name><surname>Shankle</surname><given-names>WR</given-names></name><name><surname>Elizarov</surname><given-names>A</given-names></name><name><surname>Kolb</surname><given-names>HC</given-names></name><article-title>Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>34</volume><fpage>457</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">23234879</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Roe</surname><given-names>CM</given-names></name><name><surname>Xiong</surname><given-names>C</given-names></name><name><surname>Mintun</surname><given-names>MA</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title>Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1001/archneur.64.3.noc60123</pub-id><pub-id pub-id-type="pmid">17210801</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Klunk</surname><given-names>W</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Sabbagh</surname><given-names>M</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>Reichert</surname><given-names>M</given-names></name><name><surname>Ketter</surname><given-names>N</given-names></name><name><surname>Nejadnik</surname><given-names>B</given-names></name><name><surname>Guenzler</surname><given-names>V</given-names></name><name><surname>Miloslavsky</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Lull</surname><given-names>J</given-names></name><name><surname>Tudor</surname><given-names>IC</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><name><surname>Yuen</surname><given-names>E</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><name><surname>Brashear</surname><given-names>HR</given-names></name><collab>Bapineuzumab 301 and 302 Clinical Trial Investigators</collab><article-title>Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>322</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1304839</pub-id><pub-id pub-id-type="pmid">24450891</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Xu</surname><given-names>YC</given-names></name><name><surname>Cha</surname><given-names>RH</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>PC</given-names></name><name><surname>Edland</surname><given-names>SD</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Tangalos</surname><given-names>EG</given-names></name><name><surname>Kokmen</surname><given-names>E</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><article-title>Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia</article-title><source>Neurology</source><year>2002</year><volume>58</volume><fpage>750</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1212/WNL.58.5.750</pub-id><pub-id pub-id-type="pmid">11889239</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Gilman</surname><given-names>S</given-names></name><name><surname>Koller</surname><given-names>M</given-names></name><name><surname>Black</surname><given-names>RS</given-names></name><name><surname>Jenkins</surname><given-names>L</given-names></name><name><surname>Griffith</surname><given-names>SG</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Eisner</surname><given-names>L</given-names></name><name><surname>Kirby</surname><given-names>L</given-names></name><name><surname>Rovira</surname><given-names>MB</given-names></name><name><surname>Forette</surname><given-names>F</given-names></name><name><surname>Orgogozo</surname><given-names>JM</given-names></name><collab>AN1792(QS-21)-201 Study Team</collab><article-title>Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>1553</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000159740.16984.3C</pub-id><pub-id pub-id-type="pmid">15883316</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="other"><name><surname>Boccardi</surname><given-names>M</given-names></name><name><surname>Bocchetta</surname><given-names>M</given-names></name><name><surname>Ganzola</surname><given-names>R</given-names></name><name><surname>Robitaille</surname><given-names>N</given-names></name><name><surname>Redolfi</surname><given-names>A</given-names></name><name><surname>Duchesne</surname><given-names>S</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><article-title>EADC-ADNI Working Group on The Harmonized Protocol for Hippocampal Volumetry and for the Alzheimer&#x02019;s Disease Neuroimaging Initiative: <bold>Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation</bold></article-title><source>Alzheimers Dement</source><year>2013</year><comment>May 21. doi: 10.1016/j.jalz.2013.03.0013</comment></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Holland</surname><given-names>D</given-names></name><name><surname>McEvoy</surname><given-names>LK</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><collab>Alzheimer&#x02019;s Disease Neuroimaging Initiative</collab><article-title>Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI</article-title><source>Hum Brain Mapp</source><year>2012</year><volume>33</volume><fpage>2586</fpage><lpage>2602</lpage><pub-id pub-id-type="doi">10.1002/hbm.21386</pub-id><pub-id pub-id-type="pmid">21830259</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Daams</surname><given-names>M</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Brashear</surname><given-names>HR</given-names></name><name><surname>Arrighi</surname><given-names>HM</given-names></name><name><surname>Bechten</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>K</given-names></name><name><surname>McGovern</surname><given-names>M</given-names></name><name><surname>Wattjes</surname><given-names>MP</given-names></name><article-title>An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion</article-title><source>AJNR Am J Neuroradiol</source><year>2013</year><volume>34</volume><fpage>1550</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A3475</pub-id><pub-id pub-id-type="pmid">23436056</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Moseley</surname><given-names>M</given-names></name><article-title>Diffusion tensor imaging and aging - a review</article-title><source>NMR Biomed</source><year>2002</year><volume>15</volume><fpage>553</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1002/nbm.785</pub-id><pub-id pub-id-type="pmid">12489101</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>SC</given-names></name><name><surname>Schmitz</surname><given-names>TW</given-names></name><name><surname>Moritz</surname><given-names>CH</given-names></name><name><surname>Meyerand</surname><given-names>ME</given-names></name><name><surname>Rowley</surname><given-names>HA</given-names></name><name><surname>Alexander</surname><given-names>AL</given-names></name><name><surname>Hansen</surname><given-names>KW</given-names></name><name><surname>Gleason</surname><given-names>CE</given-names></name><name><surname>Carlsson</surname><given-names>CM</given-names></name><name><surname>Ries</surname><given-names>ML</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Alexander</surname><given-names>GE</given-names></name><article-title>Activation of brain regions vulnerable to Alzheimer&#x02019;s disease: the effect of mild cognitive impairment</article-title><source>Neurobiol Aging</source><year>2006</year><volume>27</volume><fpage>1604</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.09.017</pub-id><pub-id pub-id-type="pmid">16226349</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Lorenzi</surname><given-names>M</given-names></name><name><surname>Beltramello</surname><given-names>A</given-names></name><name><surname>Mercuri</surname><given-names>NB</given-names></name><name><surname>Canu</surname><given-names>E</given-names></name><name><surname>Zoccatelli</surname><given-names>G</given-names></name><name><surname>Pizzini</surname><given-names>FB</given-names></name><name><surname>Alessandrini</surname><given-names>F</given-names></name><name><surname>Cotelli</surname><given-names>M</given-names></name><name><surname>Rosini</surname><given-names>S</given-names></name><name><surname>Costardi</surname><given-names>D</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><article-title>Effect of memantine on resting state default mode network activity in Alzheimer&#x02019;s disease</article-title><source>Drugs Aging</source><year>2011</year><volume>28</volume><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.2165/11586440-000000000-00000</pub-id><pub-id pub-id-type="pmid">21250762</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>WT</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Detre</surname><given-names>JA</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><article-title>Distinct cerebral perfusion patterns in FTLD and AD</article-title><source>Neurology</source><year>2010</year><volume>75</volume><fpage>881</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f11e35</pub-id><pub-id pub-id-type="pmid">20819999</pub-id></mixed-citation></ref></ref-list></back></article>